The General Hospital Corporation

Massachusetts Institute of Technology

Other

The Brigham and Women's Hospital, Inc.

Dana-farber-cancer Institute Inc.

Oregon Health & Science University

Genetics Institute, Inc.

Massachusetts General Hospital Corporation

The General Hospital Corporation D/b/a Massachusetts General Hospital

Bruce D Walker

Darrell J Irvine

John M McCoy

J Christopher Love

Benjamin L Ebert

Zhijian Lu

Stephen H Herrmann

Navin Varadarajan

John Christopher Love

Stephen L Swanberg

Richard Bradley Jones

Rafick-Pierre Sekaly

W Nicholas Haining

Kei Ouchi

Marcus Altfeld

Elias Haddad

Otto Yang

Quentin Eichbaum

Ralf Geiben Lynn

Boris Julg

Georg Lauer

The invention provides compositions and methods for delivering an agent to virally infected tissues and/or cells of a subject by conjugating agent-loaded nanoparticles to virus-specific T cells, such as cytotoxic T lymphocytes. The agent may be a latency-reversing drug (LRD), an antiviral agent and/or an agent that enhances cytotoxic efficacy of T lymphocytes.

Methods and compositions for localized delivery of agents to virally infected cells and tissues

The invention provides a method of analyzing interactions between pairs of target and effector cells utilizing high-throughput screenings methods for profiling large numbers of single cells in microarrays.

Compositions and methods for assessing cytotoxicity of single cells

The invention relates to expression profiles of HIV-specific T-cells and their methods of use, including but not limited to treatment of HIV, increasing T-cell function and/or survival in HIV infected subjects, monitoring HIV disease progression and classifying HIV infected subjects as controllers or chronic progressors.

Biomarkers to identify HIV-specific T-cell subsets

Modulation of PD-1 activity in the presence or absence of an agent as measured by a gene expression profile of at least two genes is provided. Reagents, kits, methods and uses thereof for the modulation of immune function comprise the identification of modulators of PD-1 activity.

Determining whether a test compound modulates PD-1 activity in activated immune cells using gene expression profiles

The invention includes compositions comprising substantially purified serpin that are useful in methods for the treatment and prevention of HIV infection. The invention also includes methods for the treatment and prevention of HIV infection comprising contacting a composition of the invention with a human patient or treating HIV infection by introducing into a cell susceptible to HIV infection a DNA molecule encoding a serpin. Additionally, the invention includes antibodies and kits useful in the detection, treatment, and prevention of HIV infection.

Method of decreasing the infectivity of HIV in a biological sample through the administration of S-antithrombin

The invention provides compositions containing HCV epitopes, which are recognized by cytotoxic T lymphocytes. Such polypeptides are used in prophylactic vaccines, immunotherapies, and assays to monitor the progress or success of immune interventions. The compositions are optimized to elicit an immune response in a genetically-diverse population of individuals.

Epitopes of hepatitis C virus

The invention features an immunogenic composition containing a frequently-recognized epitope of an HIV-1 accessory protein such as Vpr and methods of inducing an immune response using such an epitope. The epitope peptide contains the amino acid sequence ALIRILQQL of a functionally active domain or a structural domain of the accessory protein.

Methods of inducing an HIV specific response using a Vpr-specific epitope

This invention provides polynucleotides comprising sequences encoding amino-terminal-modified chemokines, the encoded amino-terminal-modified chemokines, and uses thereof.

Chemokine with amino-terminal modifications

A method of producing an HIV-specific helper T cell response in an animal by (1) providing a polypeptide 8 to 50 amino acid residues in length and having a helper T cell epitope of a HIV-1 p24 peptide; and (2) administering to the animal an amount of the polypeptide sufficient to produce an HIV-specific helper T cell response.

Method of eliciting anti-HIV-1 helper T cell responses

Growing community of inventors

Nahant, MA, United States of America

Bruce D Walker